Back to Screener

Bausch Health Companies Inc (BHC)

Price$5.31
Value ScoreB
Growth ScoreC
Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-28.96%
Price vs S&P 500 (4W)-8.36%
VGM Score57.16
Market Capitalization$2.77B
P/E Ratio (Annual)12.75x

All Metrics

P/CF (Annual)1.43x
Book Value / Share (Quarterly)$1.51
P/TBV (Annual)88.46x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)8.11%
Cash Flow / Share (Quarterly)$2.65
Price vs S&P 500 (YTD)-32.36%
Gross Margin (TTM)71.04%
Net Profit Margin (TTM)-11.47%
EPS (TTM)$-3.24
10-Day Avg Trading Volume0.43M
EPS Excl Extra (TTM)$-3.24
Revenue Growth (5Y)5.04%
EPS (Annual)$0.42
ROI (Annual)-2.29%
Gross Margin (Annual)70.65%
Net Profit Margin (5Y Avg)-3.94%
Cash / Share (Quarterly)$3.48
P/E Basic Excl Extra (TTM)13.34x
Revenue Growth QoQ (YoY)11.73%
P/E Normalized (Annual)12.75x
ROA (Last FY)0.60%
Revenue Growth TTM (YoY)8.22%
EBITD / Share (TTM)$4.65
ROE (5Y Avg)-91.99%
Operating Margin (TTM)7.12%
Cash Flow / Share (Annual)$2.68
P/B Ratio3.74x
P/B Ratio (Quarterly)12.68x
Net Income / Employee (Annual)$7,700
EV / Revenue (TTM)2.04x
Net Interest Coverage (TTM)1.23x
ROA (TTM)-4.60%
EV / EBITDA (TTM)12.38x
EPS Incl Extra (Annual)$0.42
Current Ratio (Annual)1.47x
Quick Ratio (Quarterly)0.77x
3-Month Avg Trading Volume0.47M
52-Week Price Return16.51%
EV / Free Cash Flow (Annual)21.65x
P/E Incl Extra (TTM)13.34x
Revenue / Employee (TTM)$518,800
Tangible BV / Share (Quarterly)$0.61
P/S Ratio (Annual)0.20x
Asset Turnover (Annual)0.39x
52-Week High$11.97
Operating Margin (5Y Avg)13.50%
EPS Excl Extra (Annual)$0.42
CapEx CAGR (5Y)5.66%
Tangible BV CAGR (5Y)-21.06%
26-Week Price Return-13.03%
Quick Ratio (Annual)0.88x
13-Week Price Return-10.40%
Total Debt / Equity (Annual)44.72x
Current Ratio (Quarterly)1.32x
Enterprise Value$21.50B
Revenue / Share Growth (5Y)3.90%
Asset Turnover (TTM)0.40x
Book Value / Share Growth (5Y)-38.57%
Revenue / Employee (Annual)$505,700
Inventory Turnover (Annual)1.87x
Pretax Margin (Annual)3.57%
Cash / Share (Annual)$3.53
3-Month Return Std Dev37.89%
Gross Margin (5Y Avg)71.01%
Net Income / Employee (TTM)$-59,500
EBITDA CAGR (5Y)5.64%
EBITDA Interim CAGR (5Y)13.37%
ROE (Last FY)-104.67%
Net Interest Coverage (Annual)0.44x
EPS Basic Excl Extra (Annual)$0.42
P/FCF (TTM)2.02x
Receivables Turnover (TTM)4.94x
EV / Free Cash Flow (TTM)21.74x
Total Debt / Equity (Quarterly)44.72x
EPS Incl Extra (TTM)$-3.24
Receivables Turnover (Annual)4.57x
ROI (TTM)-2.25%
P/S Ratio (TTM)0.19x
Pretax Margin (5Y Avg)-2.57%
Revenue / Share (Annual)$27.38
Tangible BV / Share (Annual)$0.12
Forward P/E1.23x
Free OCF CAGR (5Y)4.37%
Price vs S&P 500 (52W)-11.70%
P/E Ratio (TTM)13.34x
Year-to-Date Return-22.25%
5-Day Price Return-4.02%
EPS Normalized (Annual)$0.42
ROA (5Y Avg)-1.17%
Net Profit Margin (Annual)1.53%
Month-to-Date Return-4.88%
Cash Flow / Share (TTM)$1.20
EBITD / Share (Annual)$7.94
Operating Margin (Annual)19.24%
LT Debt / Equity (Annual)44.72x
P/CF (TTM)1.41x
ROI (5Y Avg)-4.82%
P/E Excl Extra (TTM)13.34x
LT Debt / Equity (Quarterly)44.72x
EPS Basic Excl Extra (TTM)$-3.24
P/TBV (Quarterly)24.24x
P/B Ratio (Annual)12.68x
Inventory Turnover (TTM)1.90x
Pretax Margin (TTM)-8.93%
Book Value / Share (Annual)$1.51
Price vs S&P 500 (13W)-20.15%
Beta1.32x
P/FCF (Annual)2.02x
Revenue / Share (TTM)$28.25
ROE (TTM)-96.76%
52-Week Low$6.06
vGradeB
gGradeC
mGradeC
vgmGradeC
Show chart for

Analyst Recommendations

Feb 2026
Mar 2026
Apr 2026
May 2026
2.44
2.44
2.44
2.44

Industry Peers — Pharmaceuticals(550)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
BHCBausch Health Companies Inc
BCC$5.31
LLYEli Lilly & Co.DBB$1082.20
JNJJohnson & JohnsonCCC$223.51
ABBVABBVIE INC.DCC$212.93
MRKMerck & Co., Inc.CCC$115.17
NVSNovartis AGCCC$145.68
AZNAstraZeneca PLCDBC$179.71
NVONovo-Nordisk A/SBBC$44.07
PFEPfizer Inc.BCC$25.63
ABTAbbott LaboratoriesCCD$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary SharesCCC$34.64

About

Bausch Health Companies is a diversified global pharmaceutical and medical device company focused on specialty care markets including gastroenterology, hepatology, neurology, and dermatology. Revenue is driven by its portfolio of branded products across Bausch + Lomb (eye care, largest segment), Salix (gastroenterology), Solta Medical (aesthetics), and other diversified products.